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Simple Summary: A platform and normalization bias agnostic single sample classifier (SSC) is
needed. A random forest SSC (MiniABS) utilizing 11 genes was developed and validated. MiniABS
surpassed previous classifiers and can be applied on multiple platforms. MiniABS may provide a
cost-effective strategy for the diagnosis of breast cancer.
Abstract: While intrinsic molecular subtypes provide important biological classification of breast
cancer, the subtype assignment of individuals is influenced by assay technology and study cohort
composition. We sought to develop a platform-independent absolute single-sample subtype classifier
based on a minimal number of genes. Pairwise ratios for subtype-specific differentially expressed
genes from un-normalized expression data from 432 breast cancer (BC) samples of The Cancer Genome
Atlas (TCGA) were used as inputs for machine learning. The subtype classifier with the fewest number
of genes and maximal classification power was selected during cross-validation. The final model was
evaluated on 5816 samples from 10 independent studies profiled with four different assay platforms.
Upon cross-validation within the TCGA cohort, a random forest classifier (MiniABS) with 11 genes
achieved the best accuracy of 88.2%. Applying MiniABS to five validation sets of RNA-seq and
microarray data showed an average accuracy of 85.15% (vs. 77.72% for Absolute Intrinsic Molecular
Subtype (AIMS)). Only MiniABS could be applied to five low-throughput datasets, showing an
average accuracy of 87.93%. The MiniABS can absolutely subtype BC using the raw expression levels
of only 11 genes, regardless of assay platform, with higher accuracy than existing methods.
Keywords: breast cancer; subtyping; classifier; machine learning; optimization
1. Introduction
During the past two decades, a series of meta-analyses of prospective randomized clinical trials for
early breast cancer conducted by the Early Breast Cancer Trialists’ Collaborative Group have produced
definitive treatment guidelines [1]. In parallel, the description of intrinsic molecular subtypes by Perou
et al. in 2000 revolutionized our understanding of the heterogeneity of breast cancer biology and its
impact on natural history and treatment response [2].
Perou’s initial description of the intrinsic subtype was through an unsupervised clustering and
did not provide a classifier for a new single sample (i.e., single sample classifier; SSC) outside the study
cohort [2]. The intrinsic subtype classifier has evolved over time into its final form—PAM50 SSC [3].
PAM50 SSC assigns a case based on the nearest distance (closest correlation) to subtype centroids of the
50 most robust classifier genes constructed from a fixed reference patient cohort. Although PAM50 SSC
has been adopted as the gold standard in The Cancer Genome Atlas (TCGA) and many other studies,
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PAM50 SSC has its limitations due to its relativistic nature. (1) Due to the need for normalization and
gene-centering (standardization) of the study cohort data before measuring each sample’s distance to
the centroids, PAM50 SSC assignment is influenced by the technology platform and the normalization
method. For example, in the TCGA dataset, overall agreement for the PAM50 subtype determined by
microarray versus RNA-seq was 83% [4]. (2) More importantly, the composition of the study cohort,
especially the proportion of ER+ tumors (for example, a trial cohort of only HER2-positive patients)
influences subtype assignments [5]. Therefore, PAM50 SSC is not an absolute classifier that can be
applied to standalone single patient data.
While subtype-specific clinical trials have gained momentum along with the development of
targeted therapies, eligibility for clinical trials is usually determined by clinical surrogate markers
(such as ER immunohistochemistry), which only moderately correlate with intrinsic subtypes defined
by gene expression profiling [6,7]. The correlative science aim of trials often includes determination
of molecular subtypes but they are conducted employing diverse technology platforms including
RNA-seq [4,8,9]. Eventually, trial results will often have to be subjected to meta-analyses to develop a
new standard of care and cross compatibility of subtype determination will be important.
In parallel, in clinical practice, the decision to use chemotherapy for ER+ tumors is aided by
gene expression-based prognostic or predictive assays such as OncotypeDx [10–12], Mammaprint [13],
or Prosigna [9,14] tests, which were developed through supervised training with survival data.
In meta-analyses with microarray data from a large cohort, all prognostic algorithms assigned the same
ER+ tumors with low proliferation (i.e., Luminal A subtype) to a low risk class. Thus, the clinical utility
of the prognostic gene expression-based tests originates from their ability to differentiate between the
Luminal A versus Luminal B subtype among ER+ breast cancer, and therefore, risk assignment by these
tests should be the same for each patient tested. However, in reality, agreement of risk assignments
among these tests is less than 50% [15,16]. This surprisingly low agreement among prognostic tests
stems from the fact that each clinical test uses a different gene expression measurement platform and
more importantly, uses a proprietary within-sample data normalization technique, in order to be
able to work with gene expression data from a single patient in contrast to a uniform, cohort-based
normalization method used for meta-analysis.
Absolute Intrinsic Molecular Subtyping (AIMS), developed by Paquet et al. [4], was the first
true SSC, since it only considers the absolute gene expression values of a given sample without
referring to their relative expression levels within a cohort. AIMS uses 100 binary rules comparing
absolute gene expression values of 151 genes to assign subtypes. While the agreement with PAM50
was ~77%, AIMS led to a more stable subtyping compared to PAM50 that was influenced by the
composition of cohorts [4]. Despite its strength and technology platform independence, AIMS cannot
be readily translated into clinical practice due to the requirement of measuring gene expression levels
of 151 genes, which typically requires microarray, RNA-seq, or NanoString. These data underscore
the clinical need to develop an absolute SSC that requires only a small number of genes and is
technology platform-independent.
We developed MiniABS (Mini Absolute Breast Cancer Subtyper) using a Random Forest model
of pairwise gene expression ratios among 11 functional genes. With a systematic gene selection
and reduction step, we aimed to minimize the size of the gene set without losing the functional
interpretability of the classifier. We validated the model’s performance using a large, heterogeneous
cohort that consists of multiple public datasets across four different technology platforms. We anticipate
that the high accuracy and reproducibility of MiniABS may provide an SSC at a low cost, as well as
providing a method for cross comparison among gene expression datasets generated with different
technology platforms for meta-analyses of clinical trials data.
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2. Results
2.1. Overview of MiniABS
The main goal of MiniABS is to construct an absolute single sample classifier to subtype breast
cancer with a minimal gene set. The entire process through which we developed MiniABS is illustrated
in Figure 1. Machine learning classifiers were trained with a large-scale public database of breast
cancer gene expression data annotated with PAM50 subtypes. To select informative genes for the
classification of subtypes, a ranked list of genes significantly up- or down-regulated in only one of the
five subtypes (subtype-specific differentially expressed genes, ssDEGs) was extracted by performing
a Wilcoxon rank-sum test. We started from five 1st level genes from the ranked list of ssDEGs and
stepwisely added the five genes from the next level down to the fifth level. Then, four well-known
subtype marker genes, ESR1, PGR, ERBB2, and MKI67 [17,18], were used as seed genes and stepwisely,
five genes were added from each level of the ssDEGs from the top five levels. For each input gene set,
expression ratios between all possible combinations of gene pairs were log2(RPKM+1)-transformed
and pairwise gene expression ratios (PGER) were calculated and used as actual inputs in the machine
learning training (Table S4). In the training phase, the classifier with the smallest gene set, but maximal
classification power, was selected as an initial model, which was further tested on an independent
validation cohort to confirm its accuracy. Detailed dataset information and acquisition processes are
provided in Table S1. When genes were ranked based on the importance of PGER in the initial model
in the training phase, we noted a remarkable decrease in importance between the top 7 and 8 genes.
Thus, model optimization to reduce the size of the gene set was performed by sequentially deducting
genes one by one from the lowest rank (13th) to the 7th gene, after which the model was rebuilt without
the removed genes in the same way applied in the training phase using the PGER matrices of these
genes. The best performing model was selected as the final model for MiniABS. The TCGA test set
was then used to test the accuracy of the finalized MiniABS, before moving on to the next step of
independent validation across different technology platforms. We further tested it on an independent
validation cohort to confirm its accuracy.
Figure 1. Overview of MiniABS. To identify the features used to classify the molecular subtypes of
the model, subtype-specific DEGs (ssDEGs) were identified using the Wilcoxon rank-sum test. We set
up an input gene set for gene selection with the ability to classify subtypes with a minimal gene set.
Four well-known machine learning models with pairwise gene expression ratios (PGERs) were used
to learn and optimize the models. The model with the best accuracy was selected. The performance
thereof was evaluated by applying the model to the test set from the discovery set. Finally, we evaluated
whether the final selected model (MiniABS) works well with an independent validation dataset and
has robustness.
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2.2. Training and Optimization of the Classifiers
The top-ranked ssDEGs from the TCGA BRCA dataset are shown in Table 1 (Table S2 for the
full list). We found that over- or under-expression of MLPH (q = 8.2 × 10−37), FGFR4 (q = 4.3 × 10−15),
CEP55 (q = 1.2 × 10−46), and KRT17 (q = 6.8 × 10−17) were identified as the top subtype-specific
genes in Basal-like, Her2E, LumA, and LumB, respectively, with high statistical significances (Table 1).
Similarly, subtype-specific expression of the four seed genes (ESR1, ERBB2, PGR, and MKI67) was
confirmed (q = 1.96 × 10−18~7.95 × 10−41) (Table S3).
By combining the ssDEGs and seed genes, five input gene sets were constructed (Figure 2A).
Briefly, each set from a kth-level ssDEG subset consists of 4 + 5 k genes (seed genes + top-kth ranked
ssDEGs from each of the five subtypes); however, the actual number was fewer due to overlap between
seed genes and ssDEGs. For each input gene set, paired gene expression ratios (PGER) were calculated
and fed into 28 classifiers, which encompassed four different machine learning algorithms (support
vector machine (SVM) with radial kernel, classification and regression tree (CART), random forest
(RF), and naïve Bayes (NB)) times seven distinct slack margin variables (α) that control the level
of confidence.
Figure 2. Optimization and performance of MiniABS. (A) Input gene set. The red lettering corresponds
to the seed genes. (B) Cross-validation accuracy according to levels in the input gene set. The red arrow
corresponds to best accuracy. (C) Mean decrease in Gini for the input gene set. Degrees of decrease in
purity when splitting occurs during training after the top seven genes are reduced. (D) Cross-validation
accuracy according to number of genes. The red arrow corresponds to best accuracy. In the case of
modeling with fewer than 11 genes, we can see that the accuracy decreases sharply. (E) Confusion
matrix of the test set (N = 85) of TCGA BRCA. The numbers in the boxes indicate the number of samples,
and the units on the color bar represent the concordance rate per subtype. The MiniABS clearly shows
better overall accuracy than AIMS, and in particular, the LumA was correctly assigned the most with
MiniABS than AIMS.
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Table 1. Top ssDEGs for five subtypes.
Rank
Basal-Like ssDEGs Her2E ssDEGs LumA ssDEGs LumB ssDEGs Normal-Like ssDEGs
Symbol p-Value FDR Symbol p-Value FDR Symbol p-Value FDR Symbol p-Value FDR Symbol p-Value FDR
1 MLPH 4.0 × 10−41 8.2 × 10−37 FGFR4 4.6 × 10−19 4.3 × 10−15 CEP55 2.4 × 10−50 1.2 × 10−46 KRT17 2.0 × 10−20 6.8 × 10−17 ERBB2 5.4 × 10−3 2.4 × 10−1
2 FOXA1 9.6 × 10−40 6.6 × 10−36 GRB7 5.6 × 10−16 7.7 × 10−13 MYBL2 7.0 × 10−49 2.4 × 10−45 SFRP1 7.7 × 10−20 1.6 × 10−16 KRT14 2.3 × 10−3 2.4 × 10−1
3 FOXC1 1.0 × 10−38 3.4 × 10−35 ERBB2 1.4 × 10−15 1.6 × 10−12 MELK 3.8 × 10−47 5.2 × 10−44 KRT14 5.7 × 10−18 4.3 × 10−15 KRT5 3.0 × 10−3 2.4 × 10−1
4 ESR1 1.0 × 10−35 6.5 × 10−33 BCL2 5.2 × 10−14 2.8 × 10−11 KIF2C 7.5 × 10−47 9.6 × 10−44 KRT5 1.6 × 10−17 8.7 × 10−15 MIA 3.2 × 10−3 2.4 × 10−1
5 NAT1 1.4 × 10−35 8.1 × 10−33 ESR1 3.6 × 10−12 9.5 × 10−10 ANLN 1.2 × 10−46 1.5 × 10−43 EGFR 1.1 × 10−16 5.0 × 10−14 SFRP1 4.9 × 10−3 2.5 × 10−1
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The ssDEGs were identified by a Wilcoxon rank-sum test and ranked according to False Discovery
Rates (FDR) per subtype. Colors denote up- (red) or down- (blue) regulated genes in comparison to
median expression of the gene between the given subtype and the remaining subtypes.
Cross-validation of the classifiers showed robust accuracy of >80% for most of the trials (Figure 2B).
Of the four machine learning algorithms, RF showed the best average performance (Table S4). The effect
of α was minimal, indicating a minimal dependency on experimental noise, thereby confirming the
robustness of the classifier (Tables S5–S7). The best accuracy of the first-level input gene set (N = 8)
was 83.45%, which was further increased to 88.04% at the second level (N = 13), with an α of 1.00.
The increase in the number of genes did not confer better accuracy after second-level input (indicated
with a red arrow in Figure 2B). Therefore, we concluded that the most efficient classifier would not
require more than 13 genes.
Next, we attempted to further reduce the number of genes required for classification. We measured
mean decreases in Gini index values (the average decrease in node purity when a gene is removed) for
the 13 genes and identified two distinctive groups: a highly informative group of seven genes and
a less informative group of six genes (Figure 2C, 40.19–60.95 vs. 20.25–24.0). With the seven genes
retained, we tested if removal of one of the less informative genes would lead to a drop in accuracy
by building six more classifiers using 8 to 13 genes. We found that accuracy was maintained without
two genes (88.26% and 88.24% without GRB7 and GRB7/KRT14, respectively, compared to 88.04% for
13 genes) and started to decrease after the removal of a third gene (Figure 2D, red arrow). Therefore,
MiniABS was finally defined as an RF model of 11 genes (ESR1, PGR, ERBB2, MKI67, MLPH, FGFR1,
CEP55, KRT17, FOXA1, MYBL2, and SFRP1).
Upon validation with the TCGA test set (20% of the discovery cohort, N = 85), MiniABS showed
an accuracy of 88.24%, a 14.12% increase above AIMS (Figure 2E).
2.3. Biological Relevance of the PGERs
The actual feature components of MiniABS are PGERs, not a single gene expression level.
We analyzed feature importance and the biological relevance of the 55 PGERs generated from 11 genes.
The distribution of the top PGER values across the subtypes confirmed that the expression ratios were
subtype-specific (Figure S1A, P ranging 10−58–10−59).
The effects of PGERs on subtype specification were more clearly visible in two-dimensional (gene
× gene) space (Figure S1B), depicting subtype-specific clustering. We noted that Basal-like samples
were well clustered in many gene pairs characterized by lower expression of FOXA1 and MLPH.
This poses the possibility of building a much simpler classifier that only separates Basal-like from other
subtypes. However, unlike Basal-like, there was no single PGER that could clearly separate the other
four subtypes, implying that accurate discrimination cannot be achieved by a simple set of rules and
requires a probabilistic model like MiniABS.
2.4. Validation on Independent Datasets
The most common pitfall in classification is model over-fitting, wherein the classifier is locally
optimized to a training set and shows reduced reproducibility in independent datasets. To address this
concern, we repeated our tests on an expanded validation set of 5816 samples from 10 independent
studies with known PAM50 subtypes. As these studies were highly heterogeneous in their sizes,
cohort compositions, data scales, and generation methods, consistently accurate classification of these
sets would validate the robust performance of MiniABS (Figure S2 and Table S8).
First, we validated the performance of MiniABS in the largest single cohort dataset available
for RNA-seq with clinical follow-up and treatment data (GSE96058, N = 3409) (Table S9). There was
a good agreement between MiniABS and the author-provided PAM50 subtypes (accuracy = 76.7%,
kappa = 0.613; 95% CI = 0.590–0.635). Of note, MiniABS classified 70.0% of tumors as LumA compared
to 50.1% by PAM50, and assigned only 0.1% to the Normal-like subtype. This was due to misclassification
of 404/767 tumors from LumB and 208/225 Normal-like as LumA subtype. One obvious concern is the
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misclassification of LumB to LumA. However, there was no difference in survival of MiniABS LumA
subtype patients versus PAM50 LumA subtype patients treated by endocrine therapy, even though
more patients were classified as LumA by MiniABS (Figure 3A).
Figure 3. Kaplan–Meier survival analysis of patients treated by endocrine therapy. (A) Survival plot
for LumA and non-LumA of MiniABS versus PAM50. Survival plot for PAM50 and (B) MiniABS;
(C) AIMS; (D) PAM50none. PAM50none is a subtype of the sample identified by the genefu package
using the “none” option.
Intriguingly, endocrine therapy-treated patients who were classified as LumA by both PAM50
and MiniABS (N = 1082) had the best clinical outcome, and LumB by PAM50 alone (N = 139) had
the worst outcome, whereas those with LumB by PAM50 but LumA by MiniABS (N = 209) showed
intermediate outcomes (Figure 3B). Among 346 patients with LumB tumors by PAM50, the Cox model
showed the trend for better outcome for those misclassified as LumA by MiniABS (N = 209) compared
to those classified as LumB (N = 139) (HR = 1.5: 95% CI = 0.9–2.4, P = 0.126).
While AIMS also showed a good agreement with PAM50 (accuracy = 73.5%, kappa = 0.616: 95%
CI = 0.595–0.637), AIMS assigned more patients to the Normal-like subtype (18.0%) compared to
PAM50 (6.6%). Patterns of survival were similar to those observed for MiniABS (Figure 3C).
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The only method that enables PAM50 subtyping of standalone single sample data is using the
“none” option in the genefu package that processes the data without standardization. PAM50none
showed a moderate agreement with the author-provided PAM50 (accuracy = 75.9%, kappa = 0.599:
95% CI = 0.574–0.619). Agreement between MiniABS and PAM50none was good (accuracy = 88.8%,
kappa = 0.768: 95% CI = 0.747–0.789) compared to only moderate agreement between AIMS and
PAM50none (accuracy = 69.4%, kappa = 0.506: 95% CI = 0.484–0.529). Again, the survival pattern for
PAM50none was similar to those observed for MiniABS (Figure 3D).
Due to the use of a small number of genes, MiniABS could be tested on all datasets from the
10 studies and showed an average accuracy of 86.54% without Normal-like (Figure 4A,B), which was
~8.82% higher than that for AIMS (77.72%).
Figure 4. Accuracy in the validation dataset. (A) Accuracy in the validation dataset. The numbers in
parentheses beneath the datasets correspond to the number of samples. The lack of genes in NanoString
and qRT-PCR data prevented the application of AIMS. Bars indicate the accuracy of MiniABS (pink
bars), AIMS (green bars), and PAM50none (blue bars). The bars filled with light colors denote the
accuracy for the five subtypes, including the Normal-like subtype, and the dark color bars correspond to
the accuracy calculated after removing the Normal-like subtype. (B) Average accuracy in the validation
dataset for the total dataset, common dataset (datasets that could apply to both MiniABS and AIMS
classifiers), and each individual platform. Error bars indicate 95% confidence intervals (95% CI).
Of particular note, AIMS could not be applied to the five low-throughput datasets due to its
requirement for a large number of genes (NanoString and qRT-PCR, marked “N/A” in Figure 4A,B).
The average accuracy of MiniABS in the common datasets without Normal-like was 85.15%,
outperforming AIMS (77.72%) for both the RNA-seq and microarray platforms (85.47% vs. 83.41% in
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RNA-seq, and 84.68% vs. 69.20% in microarray) when regarding PAM50 as the gold standard (Figure 4B).
The high average accuracy for NanoString (91.11% and 84.98% without/with Normal-like, respectively)
was unexpected and noteworthy, because no such datasets were included in the training phase.
3. Discussion
In order to develop a true absolute SSC for breast cancer, we used a stepwise approach of selecting
differentially expressed genes among subtypes and used ratios of those genes as an input for machine
learning with PAM50 subtype assignment as a gold standard reference in the TCGA breast cancer
dataset. The resulting 11 genes of MiniABS showed a robust performance regardless of the technology
platform to measure gene expression. MiniABS may have utility when comparing small sample
size clinical trial cohorts with biased subtype enrichment (for example, ER+ tumors only) due to
its independence from cohort composition. Parker’s method is challenging because it is difficult to
construct an ER balanced dataset in the absence of IHC data or when imbalance is severe in the subtype
composition of the cohort. In addition, in the case of actual real cohort data, application of Parker’s
method may be limited depending on the purpose and circumstances of the study (e.g., drug responsive
studies focused on a cohort of only ER+/HER2− cases or only HER2+ cases). Furthermore, the process
of centering genes can also sensitively affect the results. While AIMS is also an absolute SSC, it requires
more genes and therefore, may be difficult to apply to low throughput technology platforms such
as qRT-PCR.
Selecting a gene subset for classification with a brute-force manner requires an extremely high load
of computation (Appendix A, Supplementary Note), which often leads to false discovery of random
gene sets. In this study, three major heuristic approaches were adopted to alleviate this problem.
First, we used a stepwise reduction when minimizing the gene set. Instead of enumerating all possible
cases, we first tried to find the upper-bound of the gene number (13 in MiniABS) at which the model
performance converges, and then, searched for the minimal gene set. Second, limiting the pool of
total genes based on their functional association further reduced the search space and the risk for
selecting a false gene. By using the PAM50 genes, we greatly reduced the number of cases by a factor
of ~1020, without a loss in accuracy. Lastly, pre-selection of four seed genes was done based on the
same rationale (i.e., securing functional relevance and model generality while reducing search space).
Again, there was no loss of model performance caused by this step. Overall, we were able to reduce
the number of cases to ~109 from ~106020 (Appendix A), which is an easily addressable size, with the
aid of ssDEG analysis, and we were able to avoid local optima problems. Therefore, by using the
PAM50 gene, which is well-studied in the breast cancer subtype, and four markers used in clinical
practice, rather than any gene, the intention was to reflect the mechanism of the breast cancer subtype
more, and will not be of limited temporal performance seen only in the training dataset. MiniABS
pursued an effort to improve performance by reflecting the mechanism of the breast cancer subtype,
while losing less information on the input used in the model than AIMS using the binary rule of gene
pairs without considering the biological significance.
The genes used in MiniABS are known to be involved in biologic characteristics, such as
proliferation (MYBL2, MKI67, and CEP55), HER2 signaling (ERBB2), growth factor signaling (FGFR4),
ER signaling (FOXA1, MLPH, ESR1, and PGR), and Basal phenotype (KRT17, and SFRP1) [19–21].
Additionally, SFRP1 is a known Basal-like marker, and MYBL2 is a LumA-specific cellular proliferation
marker [8,22]. From this study, based on the distribution of the top PGER values across the subtypes,
we observed that each subtype was able to be characterized better with subtype-specific different gene
expression ratios than single gene-specific expression (Table S2 and Figure S1, top p values within
10−58–10−59, compared to 10−19–10−50 for a single gene). For example, Her2E and LumA subtypes
could be partially characterized by ESR1/ERBB2 and PGR/MYBL2 (Figure S1) and LumA and LumB
with MYBL2/FOXA1, SFRP1/MYBL2, and MYBL2/MLPH (Figure S1). Therefore, studying differential
gene expression ratios and inter-gene interaction among breast cancer subtypes may help us to further
understand them.
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Currently, the only two regulatory approved subtyping tests for breast cancer are Prosigna
(based on the nCounter platform) and BluePrint (based on microarray or RNA-seq). These two
subtypers use proprietary algorithms and do not completely agree with research-based PAM50
assay results. More importantly, the agreement between the two was only moderate
(kappa = 0.55: 95% CI = 0.45–0.64, N = 302) in the OPTIMA Prelim trial that prospectively compared
multiple prognostic tests for breast cancer [17].
While MiniABS subtype assignment does not completely agree with PAM50, which is regarded
as the gold standard, and assigns more patients to the LumA subtype (especially LumB to LumA),
intriguingly, there was no survival difference between MiniABS LumA and PAM50 LumA patients
treated with endocrine therapy in a large validation cohort. PAM50 LumB patients misclassified as
LumA by MiniABS showed intermediate survival outcomes between LumB and those classified as
LumA by both PAM50 and MiniABS. This was true for AIMS and PAM50none. Thus, the discrepant
cases may represent tumors with intermediate characteristics between LumA and LumB and do not
reflect true misclassification.
4. Materials and Methods
4.1. Method Overview
The overall workflow is shown in Figure 1. Machine learning classifiers were trained with
un-normalized mRNA expression data (without normalization among different samples) from
TCGA annotated with PAM50 subtypes. To select informative genes for classification, genes with
a subtype-specific expression pattern were extracted. The expression ratios between all possible
informative gene-pairs (PGER) were calculated and were used as inputs of machine learning classifiers.
In the training phase, the classifier with the smallest gene set, but maximum classification power,
was selected as an initial model, which was further tested on an independent validation cohort to
confirm its accuracy. When genes were ranked based on PGER (feature) importance (Gini score index)
from the initial model in the training phase, we noted a remarkable decrease in importance between
the top 7 and 8 genes. Thus, model optimization to reduce the size of the gene set was performed by
sequentially deducting genes one by one from the lowest rank (13th) to the 7th gene, after which the
model was rebuilt without the removed genes in the same way applied in the training phase using
the PGER matrices of these genes, and the best performing model was selected as the final model
for MiniABS. The TCGA test set was then used to test the accuracy of the finalized MiniABS before
moving on to the next step of independent validation across different technology platforms. We further
tested it on an independent validation cohort to confirm its accuracy. MiniABS is publicly available at
https://sourceforge.net/projects/miniabs/.
4.2. Training Dataset
For a discovery set, we used un-normalized RNA-seq and microarray-based gene expression
data from 432 breast cancer samples from The Cancer Genome Atlas (TCGA BRCA) [7]. For model
construction, the expression values were log2-transformed. According to TCGA annotation with
PAM50, the 432 samples consisted of 76 Basal-like, 50 Her2E, 194 LumA, 105 LumB, and 7 Normal-like
subtypes. Initial training was performed using RNA-seq and microarray data were used to examine
the cross platform applicability of the developed algorithm. For RNA-seq data, we downloaded TCGA
RNAseqV1 level 3 data with RPKM expression units. For microarray data, we downloaded the Agilent
224K Gene Expression Microarray Level 1 data (Agilent two-channel using UNC custom Microarrays).
Agilent arrays, like the processing of AIMS [4], used only the channel of the tumor samples, and then,
subtracted background intensities from this value. In the process of selecting a probe representing
a gene, we selected the probe with the maximum expression value from each sample, rather than
using the standard deviation of probe expression levels to avoid the effect derived from studied cohort,
such as the number of samples and composition of subtypes, as Paquet et al. described previously [4].
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4.3. Feature Selection and Input Data (PGER Matrix) Preparation
To identify informative genes for the classification of subtypes, a ranked list of genes significantly
up- or down-regulated in only one of the five subtypes (subtype-specific differentially expressed genes,
ssDEGs) was obtained by performing a Wilcoxon rank-sum test, with a Benjamini–Hochberg false
discovery rate-corrected p value of less than 0.005.
Since classification modeling based on pairwise comparisons of this many ssDEGs would demand
too much computing power, we employed a pragmatic approach to reduce the initial search space and
the number of trials in order to build a robust and possibility interpretable classifier (Appendix A).
Thus, four well-known subtype marker genes, ESR1, PGR, ERBB2, and MKI67 [8,9], were used as seed
genes. To the list of four seed genes, five genes from each rank were added stepwise from the 1st to
the 5th level. In other words, we defined the kth-level subset as a set of top-k ranked ssDEGs genes
for each of the five subtypes: for example, the first-level subset was {MLPH, FGFR4, CEP55, KRT17,
ERBB2}, and the second-level was the first-level subset + {FOXA1, GRB7, MYBL2, SFRP1, KRT14}
(Figure 1). In total, five subsets were prepared by increasing k from 1 to 5 and were defined as the
input gene sets (seed and top-n ranked ssDEGs).
To generate the pairwise gene expression ratio (PGER) matrix to be used as an input for machine
learning training, for each input gene set, log2(RPKM+1)-transformed expression ratios between
all possible combinations of gene pairs were calculated. Given two raw expression (e.g., RPKM
in RNA-seq) values ei and ej of genes gi and gj, the pairwise gene expression ratio (PGER) rij is
calculated by:





, 1 ≤ i < j ≤ n
where n is the total number of genes in the input gene set. We assumed that the gene expression difference
at this level cannot be differentiated from experimental noise; therefore, we further transformed rij by
introducing a slack margin variable α, wherein any rij whose absolute value was smaller than α is
counted as zero.
0, if |rij| ≤ α
r’ij = rij − α, if rij > α
rij + α, if rij < −α
Finally, an m × n(n − 1)/2 matrix of gene expression ratios (r’ij) was prepared for input, for each
ssDEG subset level (1 to 5) and α (0.00, 0.01, 0.05, 0.10, 0.15, 0.20, and 1.00), wherein m is the number of
samples in the training set and (nC2) = n(n − 1)/2 is the number of possible gene pairs.
4.4. Training and Optimization of the Classifier
In the training phase, TCGA BRCA data were split into training and test datasets (4:1) using a
stratified random sampling method in Caret [23] package. Model training with five-fold cross-validation
repeated 100 times was performed on the training dataset using Caret [23] in the R package. Training
was attempted using four different machine learning algorithms: support vector machine (SVM) with
radial kernel, classification and regression tree (CART), random forest (RF), and naïve Bayes (NB).
For each model, a five-fold cross-validation, along with hyperparameter tuning using the “tuneLength”
option, was performed repeatedly 100 times. Through this process, the optimal combination of
adjustable hyperparameters in each model was automatically tuned to select the model with the best
performance. In the training phase, the classifier with the smallest gene set, but maximum classification
power, was selected as an initial model.
The importance of each gene was inferred and ranked using Gini index scores, which reflect
the importance of contributing features to the model, assigned to the features (PGER) of the initial
model determined in the training phase. When genes were ranked based on importance, we noted a
remarkable decrease in importance between the top 7 and 8 genes. Thus, model optimization to reduce
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the size of the gene set was performed by sequentially deducting genes one by one from the lowest
rank (13th) to the 7th gene, after which the model was rebuilt without the removed genes in the same
way applied in the training phase using the PGER matrices of these genes. The best performing model
was selected as the final model for MiniABS. The TCGA test set was then used to test the accuracy of
the finalized MiniABS before moving on to the next step of independent validation across different
technology platforms.
4.5. Independent Validation and Processing
The validation sets consisted of 5816 samples acquired from 10 independent studies. Detailed
dataset information and acquisition processes are provided in Table S1 [8,18,24–31]. The validation
datasets were downloaded from the NCBI’s Gene Expression Omnibus (GEO) [32] and original
publications. For Affymetrix array, in order to use the absolute expression values in a given sample,
raw data (CEL files) were processed using Robust Multi-array Average (RMA) normalization per
single sample with the R/Bioconductor affy [33] package. We selected the probe per gene with
maximum expression values from each sample. For the RNA-seq data, GSE96058 and GSE81538,
the log2(FPKM+0.1) values provided by the authors were used. As the input expression data for
array data for AIMS application, KRT17 and CENPU genes were used as 205157_s_at, 212236_x_at,
and 218883_s_at, respectively, and then, all genes were converted into Entrez IDs as required for AIMS.
The PAM50 intrinsic subtype information was obtained from the files provided in the original papers
of the authors, except for GSE41998. For GSE41998 data, we used the PAM50 subtype provided by
Prat et al. [34]. The authors of the original paper used Parker’s research-based PAM50 to assign the
molecular subtype, except for two cohorts, GSE60788 (N = 22) and Priedigkeit et al. [31] (NonoString,
N = 40), consisting of a small sample of 10 validation datasets. The genefu [35] R/Bioconductor
package with the default and “none” parameters was used to identify the subtypes of samples from
RNA-seq datasets.
4.6. Performance Assessment with and without Normal-Like
We calculated the accuracy of MiniABS both with and without the Normal-like subtype for the
validation dataset, because the Normal-like subtype is considered a controversial subtype in breast
cancer studies, which have failed to determine whether to define it as a genuine breast cancer subtype:
Normal-like subtype has been suggested as tumors containing a large amount of contamination from
normal tissue [36,37]. When applying MiniABS to the validation dataset, we used all models, consisting
of seven α values, and then, determined the most predicted subtypes as the final subtype. In rare
cases, there were instances in which two subtypes were assigned because the probabilities for the
two subtypes were the same. Even if the correct PAM50 subtype was assigned, we considered this as
misalignment and calculated accuracy accordingly.
4.7. Modeling with Seed Genes, ssDEGs, and Intrinsic Gene Set
To evaluate the effect of using the PAM50 gene set, the models were also constructed and evaluated
using an “intrinsic gene set” and ssDEGs from all genes in the RNA-seq dataset, instead of only the
PAM50 gene set. The intrinsic gene set used by Parker et al. was downloaded from GeneSigDB [38].
To evaluate the effect of using the seed genes, the models were also assessed without the seed genes.
The set of genes used in model construction and accuracy results can be seen in Tables S5–S7.
4.8. Feature Analysis
The Kruskal–Wallis test was performed to determine whether each feature, the pairwise gene
expression ratios, was significantly different among the subtypes. By using the median value of each
gene for each subtype, the pattern of expression of genes among the subtypes used in the model was
confirmed. All analyses were carried by using R statistical software, version 3.2.5.
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4.9. Statistical Analysis
The accuracy and Cohen’s K were calculated to compare the classifiers (PAM50 provided by
the authors, PAM50none using the “none” parameter of genefu, and AIMS). Kaplan–Meier and Cox
regression survival analyses were performed with overall survival as the end point. All calculations
were performed with R, version 3.2.5.
5. Conclusions
We developed a single breast cancer sample subtype classifier (MiniABS) that could accurately
be subtyped from single patient-derived gene expression data of only 11 genes with better efficiency
and without platform and normalization bias. The performance of it surpassed previously developed
classifiers and can be applied on multiplatform data. We anticipate that MiniABS could be developed
into a practical test and accelerate translational research.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/12/12/3506/s1,
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of seed genes. Table S4: Comparison of four machine learning algorithms. Table S5: Analysis of model accuracy
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Assuming N = 20,000 (the number of all known genes), the total number of cases is approximately
106020. Therefore, we cannot consider all the possible combinations of genes in model construction.
This problem can be alleviated by reducing N. If we use N = 50 instead of 20,000 (e.g., considering only
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